Rationale and design for the defibrillators to reduce risk by magnetic resonance imaging evaluation (DETERMINE) trial

Alan H. Kadish, David Bello, J. Paul Finn, Robert O. Bonow, Andi Schaechter, Haris Subacius, Christine Albert, James P. Daubert, Carissa G. Fonseca, Jeffrey Goldberger

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

DETERMINE Trial. Background: Cardiac magnetic resonance imaging (CMR) can accurately determine infarct size. Prior studies using indirect methods and CMR to assess infarct size have shown that patients with larger myocardial infarctions have worse prognoses. Implantable cardioverter defibrillators (ICD) have been shown to improve survival among patients with severe left ventricular (LV) dysfunction. However, the majority of cardiac arrests occur in patients with higher ejection fractions. Methods: The Defibrillators To Reduce Risk By Magnetic Resonance Imaging Evaluation study (DETERMINE) is a prospective, multicenter, randomized, clinical trial in patients with coronary artery disease (CAD) and mild-to-moderate LV dysfunction. The purpose of this trial is to test the hypothesis that patients with an infarct size ≥10% of LV mass, randomized to ICD plus appropriate medical therapy will have improved survival compared with patients randomized to medical therapy alone. Cine and myocardial delayed contrast CMR will be performed in patients with CAD. The primary endpoint will be death from any cause. At least 10,000 patients with CAD will undergo CMR. The target enrollment is 1,550 patients with an estimated 36-month enrollment period. The patients will be followed up for 24 months after the last patient randomization. During the follow-up period, 330 deaths are estimated to occur. This study is powered to detect a 28% reduction in mortality by ICD therapy. Conclusion: The DETERMINE trial will assess the efficacy of ICD therapy to improve survival among patients with CAD, mild-to-moderate LV dysfunction, and infarct size ≥10% of LV mass as measured by CMR. (J Cardiovasc Electrophysiol, Vol. 20, pp. 982-987)

Original languageEnglish (US)
Pages (from-to)982-987
Number of pages6
JournalJournal of Cardiovascular Electrophysiology
Volume20
Issue number9
DOIs
StatePublished - Sep 1 2009
Externally publishedYes

Fingerprint

Defibrillators
Magnetic Resonance Imaging
Implantable Defibrillators
Coronary Artery Disease
Left Ventricular Dysfunction
Survival
Therapeutics
Random Allocation
Heart Arrest
Cause of Death
Randomized Controlled Trials
Myocardial Infarction

Keywords

  • ICD
  • MRI
  • Ventricular tachycardia/fibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Rationale and design for the defibrillators to reduce risk by magnetic resonance imaging evaluation (DETERMINE) trial. / Kadish, Alan H.; Bello, David; Finn, J. Paul; Bonow, Robert O.; Schaechter, Andi; Subacius, Haris; Albert, Christine; Daubert, James P.; Fonseca, Carissa G.; Goldberger, Jeffrey.

In: Journal of Cardiovascular Electrophysiology, Vol. 20, No. 9, 01.09.2009, p. 982-987.

Research output: Contribution to journalArticle

Kadish, Alan H. ; Bello, David ; Finn, J. Paul ; Bonow, Robert O. ; Schaechter, Andi ; Subacius, Haris ; Albert, Christine ; Daubert, James P. ; Fonseca, Carissa G. ; Goldberger, Jeffrey. / Rationale and design for the defibrillators to reduce risk by magnetic resonance imaging evaluation (DETERMINE) trial. In: Journal of Cardiovascular Electrophysiology. 2009 ; Vol. 20, No. 9. pp. 982-987.
@article{6588e2d5d58341a189d8ac0feee464f1,
title = "Rationale and design for the defibrillators to reduce risk by magnetic resonance imaging evaluation (DETERMINE) trial",
abstract = "DETERMINE Trial. Background: Cardiac magnetic resonance imaging (CMR) can accurately determine infarct size. Prior studies using indirect methods and CMR to assess infarct size have shown that patients with larger myocardial infarctions have worse prognoses. Implantable cardioverter defibrillators (ICD) have been shown to improve survival among patients with severe left ventricular (LV) dysfunction. However, the majority of cardiac arrests occur in patients with higher ejection fractions. Methods: The Defibrillators To Reduce Risk By Magnetic Resonance Imaging Evaluation study (DETERMINE) is a prospective, multicenter, randomized, clinical trial in patients with coronary artery disease (CAD) and mild-to-moderate LV dysfunction. The purpose of this trial is to test the hypothesis that patients with an infarct size ≥10{\%} of LV mass, randomized to ICD plus appropriate medical therapy will have improved survival compared with patients randomized to medical therapy alone. Cine and myocardial delayed contrast CMR will be performed in patients with CAD. The primary endpoint will be death from any cause. At least 10,000 patients with CAD will undergo CMR. The target enrollment is 1,550 patients with an estimated 36-month enrollment period. The patients will be followed up for 24 months after the last patient randomization. During the follow-up period, 330 deaths are estimated to occur. This study is powered to detect a 28{\%} reduction in mortality by ICD therapy. Conclusion: The DETERMINE trial will assess the efficacy of ICD therapy to improve survival among patients with CAD, mild-to-moderate LV dysfunction, and infarct size ≥10{\%} of LV mass as measured by CMR. (J Cardiovasc Electrophysiol, Vol. 20, pp. 982-987)",
keywords = "ICD, MRI, Ventricular tachycardia/fibrillation",
author = "Kadish, {Alan H.} and David Bello and Finn, {J. Paul} and Bonow, {Robert O.} and Andi Schaechter and Haris Subacius and Christine Albert and Daubert, {James P.} and Fonseca, {Carissa G.} and Jeffrey Goldberger",
year = "2009",
month = "9",
day = "1",
doi = "10.1111/j.1540-8167.2009.01503.x",
language = "English (US)",
volume = "20",
pages = "982--987",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Rationale and design for the defibrillators to reduce risk by magnetic resonance imaging evaluation (DETERMINE) trial

AU - Kadish, Alan H.

AU - Bello, David

AU - Finn, J. Paul

AU - Bonow, Robert O.

AU - Schaechter, Andi

AU - Subacius, Haris

AU - Albert, Christine

AU - Daubert, James P.

AU - Fonseca, Carissa G.

AU - Goldberger, Jeffrey

PY - 2009/9/1

Y1 - 2009/9/1

N2 - DETERMINE Trial. Background: Cardiac magnetic resonance imaging (CMR) can accurately determine infarct size. Prior studies using indirect methods and CMR to assess infarct size have shown that patients with larger myocardial infarctions have worse prognoses. Implantable cardioverter defibrillators (ICD) have been shown to improve survival among patients with severe left ventricular (LV) dysfunction. However, the majority of cardiac arrests occur in patients with higher ejection fractions. Methods: The Defibrillators To Reduce Risk By Magnetic Resonance Imaging Evaluation study (DETERMINE) is a prospective, multicenter, randomized, clinical trial in patients with coronary artery disease (CAD) and mild-to-moderate LV dysfunction. The purpose of this trial is to test the hypothesis that patients with an infarct size ≥10% of LV mass, randomized to ICD plus appropriate medical therapy will have improved survival compared with patients randomized to medical therapy alone. Cine and myocardial delayed contrast CMR will be performed in patients with CAD. The primary endpoint will be death from any cause. At least 10,000 patients with CAD will undergo CMR. The target enrollment is 1,550 patients with an estimated 36-month enrollment period. The patients will be followed up for 24 months after the last patient randomization. During the follow-up period, 330 deaths are estimated to occur. This study is powered to detect a 28% reduction in mortality by ICD therapy. Conclusion: The DETERMINE trial will assess the efficacy of ICD therapy to improve survival among patients with CAD, mild-to-moderate LV dysfunction, and infarct size ≥10% of LV mass as measured by CMR. (J Cardiovasc Electrophysiol, Vol. 20, pp. 982-987)

AB - DETERMINE Trial. Background: Cardiac magnetic resonance imaging (CMR) can accurately determine infarct size. Prior studies using indirect methods and CMR to assess infarct size have shown that patients with larger myocardial infarctions have worse prognoses. Implantable cardioverter defibrillators (ICD) have been shown to improve survival among patients with severe left ventricular (LV) dysfunction. However, the majority of cardiac arrests occur in patients with higher ejection fractions. Methods: The Defibrillators To Reduce Risk By Magnetic Resonance Imaging Evaluation study (DETERMINE) is a prospective, multicenter, randomized, clinical trial in patients with coronary artery disease (CAD) and mild-to-moderate LV dysfunction. The purpose of this trial is to test the hypothesis that patients with an infarct size ≥10% of LV mass, randomized to ICD plus appropriate medical therapy will have improved survival compared with patients randomized to medical therapy alone. Cine and myocardial delayed contrast CMR will be performed in patients with CAD. The primary endpoint will be death from any cause. At least 10,000 patients with CAD will undergo CMR. The target enrollment is 1,550 patients with an estimated 36-month enrollment period. The patients will be followed up for 24 months after the last patient randomization. During the follow-up period, 330 deaths are estimated to occur. This study is powered to detect a 28% reduction in mortality by ICD therapy. Conclusion: The DETERMINE trial will assess the efficacy of ICD therapy to improve survival among patients with CAD, mild-to-moderate LV dysfunction, and infarct size ≥10% of LV mass as measured by CMR. (J Cardiovasc Electrophysiol, Vol. 20, pp. 982-987)

KW - ICD

KW - MRI

KW - Ventricular tachycardia/fibrillation

UR - http://www.scopus.com/inward/record.url?scp=69249170004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249170004&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8167.2009.01503.x

DO - 10.1111/j.1540-8167.2009.01503.x

M3 - Article

C2 - 19493153

AN - SCOPUS:69249170004

VL - 20

SP - 982

EP - 987

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 9

ER -